Introduction
Osteosarcoma, the most common primary bone malignancy, is the second highest cause of cancer-related death in children and young adolescents. Despite advances in multimodality treatments, the combination of neoadjuvant chemotherapy plus surgery that dramatically increased survival rates from 20 to 65% since the 1980s, the progress has been painfully slow for the past 20 years (1,2). Resistance to commonly used drugs in osteosarcoma treatment (cisplatin, epirubicin, methotrexate and ifosfamide) and local recurrence or distant metastasis represent two important mechanisms for therapy failure. Therefore, developing more targeted treatment approaches is imperative as a plateau in efficacy has been reached with current treatments (3) .
Chemoresistance and metastasis in cancer cells initiate from genetic and epigenetic changes that allow for the emergence of apoptosis-resistant cell populations with deregulated growth signals (4) . Recently, genomic imprinting, an epigenetic form of gene regulation that results in the expression of only one parental allele, was shown to not only play an important role in embryogenesis and behavioral development but also to contribute to carcinogenesis (5) . Our previous study examined global changes in the expression of imprinted genes during malignant transformation of human osteoblast hFOB1.19 cells using oligonucleotide microarrays (6) . Of the imprinted genes identified, TSSC3 (also PHLDA2: pleckstrin homology-like domain family A member 2), a homolog of the mouse TDAG51 gene, was the first apoptosis-related gene shown to be imprinted and expressed from the maternal allele in normal development. It is located within the tumor suppressor region of 11p15, and its expression was reported to be suppressed in several cases of malignant tumors (7) .
However, the functional role and apoptotic regulatory mechanism of TSSC3inosteosarcomacellsarenotfullyunderstood.Theapoptoticmachineryiscategorizedintotwomajorpathways:extrinsicdeathreceptorpathway andintrinsicmitochondriapathway (8, 9) . The former occurs through activation of cell surface death receptors-binding-specific ligands (e.g. FasL and TRAIL). FADD and TRADD are then recruited to form the death-inducing signaling complex, which in turn leads to activation of caspase-8 and -10. Flip is an important negative regulator of this apoptotic pathway. Alternatively, mitochondria as the central regulators of the intrinsic pathway are associated with the Bcl-2 protein family, which trigger the release of Cyt c into the cytosol, resulting in caspase9 activation through an association with Apaf-1 to form a caspase9 activating complex or apoptosome. The Bcl-2 family of proteins includes the proapoptotic Bax and Bak, and the antiapoptotic Bcl-2, Bcl-xl and Bcl-w. Once initiator caspases are activated, common downstream effector caspases, including caspase-3, -6, -7 and then cleave a number of cytoskeletal and nuclear proteins such as poly ADP-ribose polymerase (PARP), leading to cellular demise (10) . The ratio of antiapoptotic and proapoptotic proteins is also important in determining cell apoptosis and survival after DNA damage, and alterations in this pathway has important consequences for tumorigenesis (11) . The purpose of this study was to verify the function and apoptotic signaling pathway of TSSC3 in osteosarcoma and to further clarify the mechanisms involved in the influence of TSSC3 on chemotherapeutic effects in osteosarcoma cells.
Materials and methods

Cell lines and culture
Immortalized human osteoblast cells hFOB (hFOB1. 19) were obtained from American Type Culture Collection (ATCC, Manassas, VA) and cultured in Dulbecco's minimal essential medium/Ham's F12 (Hyclone, Logan, UT) with 10% fetal bovine serum (FBS; Gibco, Grand Island, NY), 0.3 mg/ml neomycin G418 (Gibco) and 2.5 mM L-glutamine (Sigma, St Louis, MO) at 33.5°C in a 5% CO 2 incubator. The malignant transformed hFOB cell line (MTF cells) was established by our group as described in our previous article [Li et al. (6) ]. Other human osteosarcoma cell lines SaOS2, MG63, U2OS and HOS were obtained from ATCC. These cell lines were cultured in Dulbecco's modified Eagle's medium (Gibco) supplemented with 10% FBS, 100 U/ml penicillin and 100 U/ml streptomycin (Gibco) at 37°C in a 5% CO 2 incubator. For drug treatment, cells were treated with cisplatin (DBL, Warwick, UK) and epirubicin (DBL) for 24 h or 48 h at a final concentration of 3 lg/ml and 1 lg/ml, respectively.
Tissue specimens
Tumor samples were obtained by surgical biopsy from the primary tumor sites of 24 patients with osteosarcoma prior to radiation therapy or chemotherapy. Matched non-tumor tissues were taken within 2 cm from the tumors. Donors included 10 females and 14 males with a mean age of 17 years (range 5-28 years). Tumor tissues were confirmed by pathological examination, including 13 cases of osteoblastic osteosarcoma, 6 cases of chondroblastic osteosarcoma and 5 cases of fibroblastic osteosarcoma. Fetal liver samples derived from four donors between 15 and 32 weeks gestations as well as two adult liver specimens from cases of hepatic hemangioma were used as controls. Informed study protocols were completed in accordance with the medical ethics committee of the Southwest Hospital (Chongqing, China). All tissues were immediately frozen in liquid nitrogen and stored at À80°C until use.
Abbreviations: FBS, fetal bovine serum; FITC, fluorescein isothiocyanate; mRNA, messenger RNA; PARP, poly ADP-ribose polymerase; PBS, phosphate-buffered saline; PI, propidium iodide; qRT-PCR, quantitative real-time polymerase chain reaction; TUNEL, terminal deoxynucleotidyl transferasemediated dUTP-biotin nick end labeling. Construction of TSSC3 overexpression and TSSC3 RNAi SaOS2 cell lines The GeneSwitch TM system (Invitrogen, Carlsbad, CA) was kindly provided by Cheng Qian (Institute for Pathology and Cancer Research, Southwest Hospital, Chongqing, China) and was used for overexpression of TSSC3. The sequence for human TSSC3 was obtained from Genbank (NM_001753), and the CDS of TSSC3 was amplified with the primers 5#-CCCAAGCTTATGAAATCCCCC-GACGAG-3# and 5#-CGGGATCCTCATGGCGTGCGGGGTTT-3#. The TSSC3 fragment was then ligated into the pGene/v5-His inducible expression vector. After cotransfection of the Pgene/V5-His/TSSC3 vector or Pgene/V5-His/control vector and the pSwitch regulatory plasmid into SaOS2 cells, mifepristone (30 nM) was added for 72 h to induce the maximum TSSC3 expression. As shown in Supplementary Figure 1a , available at Carcinogenesis Online, the messenger RNA (mRNA) and protein levels of TSSC3 in transfectants were analyzed by real-time polymerase chain reaction (PCR) and western blot, respectively. The SaOS2 cells stably transfected with Pgene/V5-His/TSSC3 and Pgene/V5-His/ control were designated as overTSSC3 cells and overCON cells, respectively.
The pSilencer TM 5.1 Retro Kit (Ambion, Austin, TX) was used to knock down TSSC3 expression in SaOS2 cells. An annealed siRNA template (5#-CCATAGCTGGAAGAGGCTG-3# and 5#-ATAACTTAAGGCGCCCGTG-CA-3#) was inserted into the pSilencer 5.1 Retro vector, which was then transfected into PT67 cells (retroviral packaging cells; ATCC). The transfected cells were cultured under puromycin selection until the untransfected cells were dead. Finally, SaOS2 cells were infected with the recombinant retrovirus or negative control retrovirus and cultured under puromycin selection until the cells infected with the mock viral supernatant were killed. The mRNA and protein levels of TSSC3 in transfectants were analyzed by real-time PCR and western blot (Supplementary Figure 1b is available at Carcinogenesis Online). The SaOS2 cells stably expressing pSilencer/TSSC3 and pSilencer/control were designated as siTSSC3 cells and siCON cells, respectively.
Transmission electronic microscopy
Cells were washed twice in phosphate-buffered saline (PBS), and pellets were fixed with 2.5% glutaraldehyde for 4 h at 4°C. After rinsing with cold PBS, the cells were further fixed in 1% osmium tetroxide at room temperature for 2 h. After dehydration in a graded series of ethanol and then in acetone twice for 15 min, the samples were embedded in Epon812 resin and acetone (vol/vol, 1:1) for 30 min, followed by 100% Epon812 resin for 1 h. The Epon812 resin was solidified at 37°C for 24 h and at 60°C for 48 h. Ultrathin 60-nm sections were prepared with an LKB ultramicrotome (Ultrotome NOVA; LKB, Broma, Sweden) and stained with uranylacetate and lead citrate for examination by TEM (JEM-2000Ex; JEOL Ltd, Tokyo, Japan).
Immunofluorescence
Cells were plated onto coverslips in Dulbecco's modified Eagle's medium with 10% FBS for 24 h, fixed with 4% paraformaldehyde for 20 min, incubated in 0.2% Triton X-100-PBS for 10 min at room temperature, followed by blocking with 5% goat serum at 37°C for 30 min. The cells were then incubated with primary antibodies against TSSC3 (goat polyclonal IgG, 1:100 dilution; Santa Cruz Biotechnology, Santa Cruz, CA), Ki67 (rabbit polyclonal IgG, 1:100 dilution; Santa Cruz Biotechnology), cleaved caspase3 (rabbit monoclonal IgG, 1:100 dilution; Cell Signaling Technology, Beverly, MA), pro-caspase8 (rabbit polyclonal IgG, 1:50 dilution; Santa Cruz Biotechnology), pro-caspase9 (rabbit polyclonal IgG, 1:50 dilution; Santa Cruz Biotechnology) or Bcl-2 (rabbit polyclonal IgG, 1:50 dilution; Santa Cruz Biotechnology) at 4°C overnight, followed by detection with appropriate secondary antibodies (Cy3 Red rabbit anti-goat, Cy3 Red goat anti-rabbit and fluorescein isothiocyanate (FITC) Green goat anti-rabbit; Boster, Wuhan, China). The nuclei were counterstained with Hoechst33258 (Beyotime, Shanghai, China). The immunofluorescent signals were detected by laser confocal scanning microscopy (SP-5; Leica, Germany).
Cell growth assay CCK8 assay. Cell growth was measured using the cell proliferation reagent WST-8 (Roche Biochemicals, Mannheim, Germany). After plating cells in 96-well microtiter plates (Corning Costar, Corning, NY) at 2 Â 10 3 /well, 10 ll of CCK8 were added to each well at the time of harvest, according to the manufacturer's instructions. One hour after adding CCK8, cellular viability was determined by measuring the absorbance of the converted dye at 450 nm.
Colony formation assay. Cells were plated in a six-well plate (Corning Costar) at 100, 200, 400 or 800 cells per well or at 500 cells in a culture dish. On day 16, the plates were fixed in 4% paraformaldehyde, stained with 0.1% crystal violet (Bio Basic, Amherst, NY), and the colony numbers were counted.
Cell cycle analysis
One million cells were harvested for cell cycle analysis for each sample. The cells were washed in 0.1% glucose in PBS, adjusted to 1 Â 10 6 /ml and fixed in 70% ethanol for at least 24 h. The fixed cells were resuspended in 0.1% glucose containing 50 lg/ml propidium iodide (PI) and 100 lg/ml RNase for 30 min and then analyzed by flow cytometry. Cell cycle parameters were obtained using curve fitting analysis with the ModFit program (Verity Software, Topsham, ME).
Xenografts Cells (5 Â 10 5 or 3 Â 10 5 ) were injected subcutaneously into 4-week-old female nude mice (n 5 7 for untranfected SaOS2, n 5 6 for overCON cells, n 5 11 for overTSSC3 cells, n 5 6 for siCON cells, n 5 10 for siTSSC3 cells; Center of Experimental Animals, Third Military Medical University, Chongqing, China), which were killed 7 weeks after implantation. Tissues from subcutaneous xenografts were used for histological and immunostaining examinations. The mice were maintained according to the Guidelines of Animal Experiments by Third Military Medical University.
Histology and immunohistochemistry
Tumor samples were fixed in 10% formalin, embedded in paraffin and sectioned onto slides. Before staining, the slides were deparaffinized through a series of xylene baths and rehydrated through graded ethanol baths. For histological examination, the 5 lm thick tissues sections were stained with hematoxylin and eosin. For immunohistochemistry, samples were fixed with 4% paraformaldehyde for 20 min, treated with 0.2% Triton X-100-PBS for 10 min, blocked with 3% hydrogen peroxide for 15 min at 37°C and then heated in a microwave oven with 10 mM citric acid solution to repair antigens. The samples were then incubated at 4°C with antibodies against TSSC3 and Ki67 diluted 1:100. After washing out the primary antibody, the sections were incubated at 37°C with appropriate biotinylated secondary antibodies (Zhongshan, Peking, China), and the nuclei were counterstained with hematoxylin. Negative controls without primary antibody were processed in parallel for each staining experiment. TUNEL assay. Cells were plated onto coverslips in Dulbecco's modified Eagle's medium with 10% FBS for 24 h, fixed with 4% paraformaldehyde for 20 min, blocked with 5% goat serum at 37°C for 30 min and then treated with 0.3% Triton X-100-PBS for 10 min at room temperature. An enzyme solution was added to the label solution (1:9 dilution) to obtain a terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) reaction mixture (Roche), of which 50 ll were added to each sample and incubated for 60 min at 37°C in a humidified atmosphere in the dark. For the negative controls, 50 ll of the label solution were added. The samples were analyzed by laser confocal scanning microscopy at 480 nm. The 5 lm thick tumor tissue sections collected from the mice were analyzed for the simultaneous expression of TSSC3 and presence of apoptosis-induced DNA fragmentation. Briefly, the sections were fixed with cold acetone for 20 min, blocked with 5% goat serum at 37°C for 30 min and treated with 0.3% Triton X-100-PBS for 10 min at room temperature. The sections were then incubated with primary followed by secondary antibodies against TSSC3 and then incubated with the TUNEL reaction mixture. Sections were analyzed by laser confocal scanning microscopy.
Mitochondrial membrane potential analysis (DWm). Changes in mitochondrial transmembrane potential occurring during apoptosis induced by TSSC3 transfection were examined using Mitochondrial membrane potential assay kit (Beyotime Institute of Biotechnology, Haimen, China) with JC-1 (lipophilic cation 5,5#,6,6#-tetrachloro-1,1#,3,3#-tetraethylbenzimidazolcarbocyanine iodide). Briefly, overCON cells and overTSSC3 cells (5 Â 10 5 ) were seeded into sixwell plates. After overnight growth, the cells were incubated with 1 ml JC-1 working solution in a CO 2 incubator for 20 min. The staining solution was removed and cells were washed with JC-1 staining buffer twice and then analyzed by fluorescence microscopy using a band-pass filter (Fluorescein and Cy3). The depolarizing agent CCCP (10 lM) was used as a positive control.
Reverse transcription-PCR and quantitative real-time PCR analyses
Total RNA was isolated from cultured cells using TRIzol reagent (TakaRa, Dalian, China) according with the manufacturer's protocol, and the concentration was determined spectrophotometrically at A260. Total RNA (500 ng) was used to synthesize the first complementary DNA strand using the PrimerScript TM RT reagent Kit (TakaRa) following the instructions of the manufacturer. Optimal PCR conditions were as follows: denaturation at 94°C for 5 min, 32 cycles of 94°C for 30 s, 30 s annealing, 72°C for 30 s and a 72°C extension for 10 min. Amplified reverse transcription-PCR products were electrophoresed on a 1% agarose gel with ethidium bromide and analyzed by Quantity One software TSSC3 mediates apoptosis in osteosarcoma (Bio-Rad Laboratories, Hercules, CA Western blot analysis Cells were lysed in lysis buffer [10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 1% Nonidet P-40, 1% Triton-X and Halt Protease and Phosphatase Inhibitor Cocktail (Pierce, Rockford, IL)], and centrifuged at 15 000g for 20 min at 4°C in order to remove insoluble materials. Total protein was then measured by a BCA protein assay kit (Pierce). Approximately 100 lg of total protein was separated in a 12% sodium dodecyl sulfate-polyacrylamide gel and transferred onto a phenylmethylsulfonyl fluoride membrane (Invitrogen). Membranes were blocked with 5% fat-free milk for 2 h at room temperature and subsequently incubated with antibodies against GAPDH (rabbit monoclonal IgG, 1:1000 dilution; Cell Signaling Technology), TSSC3 (rabbit polyclonal IgG, 1:100 dilution; Abcam, Hong Kong, China), cleaved caspase3 (rabbit monoclonal IgG, 1:100 dilution; Cell Signaling Technology), Fas (rabbit monoclonal IgG, 1:200 dilution; Cell Signaling Technology), Cytochrome C (mouse monoclonal IgG, 1:500 dilution; Abcam) or cleaved PARP (mouse monoclonal IgG, 1:100 dilution; Cell Signaling Technology) overnight at 4°C. After washing with Modified D-PBS Tween-20, the membranes were incubated at 37°C for 2 h with an appropriate secondary antibody (anti-mouse or anti-rabbit IgG at a 1:2000 dilution; Zhongshan). Immunoreactivity was detected using an ECL Kit (Pierce) according to the instructions of the manufacturer. The results were analyzed using Image LabTM Software (Bio-Rad Laboratories), and all the targeted genes were normalized to GAPDH.
Subcellular location prediction
Hum-mPLoc was used to predict TSSC3 protein subcellular location based on all human protein entries in the UniProtKB database (Swiss-Prot þ TrEMBL), which contains 4 949 164 protein sequences (12, 13) . The human TSSC3 protein sequence (accession number: AAC51912.1) entered into the program for the analysis was MKSPDEVLREGELEKRSDSLFQLWKKKRGVLTSDRLSLF-PASPRARPKELRFHSILKVDCVERTGKYVYFTIVTTDHKEIDFRCAGESC WNAAIALALIDFQNRRALQDFRSRQERTAPAAPAEDAVAAAAAAPSEPS EPSRPSPQPKPRTP.
Statistical analysis
All experiments were repeated three times. Mean values and standard deviations were calculated, and the statistical significance was determined using Student's t-test. Comparisons with P , 0.05 were considered statistically significant. All statistical analyses were performed using SPSS13.0 software.
Results
TSSC3 is lowly expressed in human osteosarcoma cell lines and tissues
We previously observed the differential expression of TSSC3 mRNA between hFOB1.19 osteoblasts and malignant transformed hFOB1.19 (MTF) osteoblasts by microarray analysis (6) . To validate this observation here, TSSC3 expression in the two cell lines was analyzed by quantitative real-time (qRT-PCR). We found that TSSC3 expression in MTF osteoblasts was significantly lower (P , 0.001) than that in hFOB1.19 osteoblasts (Figure 1a) , suggesting that TSSC3 expression was downregulated by $50% during osteosarcoma transformation.
Previous studies have reported that downregulation of TSSC3 is associated with cancer progression. To confirm this, we used reverse transcription-PCR and immunofluorescence to examine TSSC3 mRNA and protein expression levels, respectively, in hFOB1.19 osteoblasts and other osteosarcoma cell lines (Figure 1b) . TSSC3 expression in hFOB1.19 osteoblasts was higher than that in all osteosarcoma cell lines, and it appeared to be much higher in HOS or MG63 cell lines (from low-grade osteosarcoma) than in U2OS or SaOS2 cell lines (from high-grade osteosarcoma). Immunofluorescence analysis confirmed the reverse transcription-PCR results (Figure 1c ). Although the analysis using the Hum-mPLoc server 2.0 (described in Materials and Methods) showed that the derived complementary DNA sequence contains a putative nuclear localization signal (data not shown), microscopic examination of the stained human osteoblast and osteosarcoma cells indicated that at least in these cells, TSSC3 was localized primarily to the cytoplasm. We proceeded to confirm the observations above in an independent set of osteosarcomas from patients by analyzing TSSC3 expression using reverse transcription-PCR in 24 primary osteosarcomas. Of the 24 osteosarcoma cases, 11 (45.8%) were positive (mean absorbance intensity of 0.18 ± 0.03). In contrast, most of the matched non-tumor tissues (79.1%) showed positive TSSC3 expression (mean absorbance intensity of 0.52 ± 0.05) (Figure 1d) . The results revealed that TSSC3 mRNA was significantly lower in human osteosarcomas than in matched non-tumor tissues. Although the differences in TSSC3 expression between osteosarcoma cases and their matched non-tumor tissues were statistically significant, no notable associations between the loss of TSSC3 mRNA expression and clinicopathological parameters, such as gender, age and histopathological classification were observed (Supplementary Table 2 is available at Carcinogenesis Online). These results suggested that low expression of TSSC3 was associated with osteosarcoma transformation and progression. The effect of TSSC3 on SaOS2 cell growth was investigated by CCK8 and plate colony formation assays. OverTSSC3 cells grew more slowly than the controls (Figure 2a, left) , and the difference was more pronounced after day 2 when essentially all cells had established cell-cell contacts. As expected, TSSC3 knockdown increased the SaOS2 cell growth (Figure 2a, right) , and the difference between siTSSC3 cells and the controls became significant on day 5. Cells overexpressing TSSC3 had remarkably reduced efficiency in forming large colonies (.100 cells) from 17.75 ± 0.01%-0.67 ± 0.01%, 26.5-fold lower than that of overCON cells. Conversely, TSSC3 knockdown significantly increased the number of colonies from 80 ± 7 to 276 ± 21, and the individual colony sizes were notably larger than those of the controls (Figure 2b and c) , suggesting that TSSC3 decreased the autonomous growth potential of osteosarcoma cells.
Immunofluorescence analysis of Ki67 expression, a marker for active proliferation of cancer cells, was also performed. Concomitant with a decrease in cell proliferation, TSSC3 upregulation markedly reduced Ki67 expression, whereas TSSC3 downregulation obviously enhanced it compared with the control (Figure 2d and e) . Taken together, these results demonstrated that cell proliferation was inhibited by TSSC3 in vitro.
The cell cycle distribution of a population is highly indicative of changes in cell proliferation, apoptosis, differentiation and senescence, which may lead to carcinogenesis. Compared with the controls, accumulation of overTSSC3 cells in the G 0 /G 1 phase increased, whereas TSSC3 downregulation reduced this subpopulation (Supplementary Table 3 is available at Carcinogenesis Online), indicating that TSSC3 induced osteosarcoma cell cycle arrest.
To further investigate the growth regulatory effects of TSSC3 in an in vivo setting, 5 Â 10 5 cells were subcutaneously injected into athymic nude mice, and tumor sizes were measured every 3-5 days for 7 weeks. Only 2 of 11 mice implanted with overTSSC3 cells developed a tumor. However, overCON cells (n 5 6) and untransfected SaOS2 (n 5 7) formed more rapidly growing tumors in the majority of the mice inoculated (Supplementary Table 4 is available at Carcinogenesis Online). Notably, a 4 weeks period was required for overTSSC3 cells compared with a 2 weeks period for the controls to generate tumors of $1 cm in diameter. Moreover, the injected overTSSC3 cells resulted (Figure 3a  and b) . The mean size of overTSSC3 cell-derived tumors was reduced by 87% at 7 weeks. Conversely, we observed tumor formation in 100% of mice (n 5 10) injected with 3 Â 10 5 siTSSC3 cells relative to 67% of mice injected with 3 Â 10 5 siCON cells. The tumors formed from siTSSC3 cells not only were considerably larger (increased tumor volume from 66.10 ± 24.64 mm 3 to 153.45 ± 42.38 mm 3 at 5 weeks) but also had a shortened latent period from 2 weeks to 1 week (Supplementary Table 4 is available at Carcinogenesis Online).
Hematoxylin-and eosin-stained specimens obtained from subcutaneous tumors are shown in Figure 3c . The siTSSC3 cell-derived and untransfected SaOS2 cell-derived tumors contained numerous hyperchromatic nuclei with karyokinesis, pleomorphism (Figure 3c , red arrow), necrosis (Figure 3c , black arrow) and high density of microvessels, typically seen in human osteosarcoma. In tumors formed by overTSSC3 cells, no necrosis or karyokinesis was observed, and they had low microvessel densities. These results indicated that tumors derived from siTSSC3 cells displayed osteosarcoma features closer to that of clinical tumors. As expected, tumors from the overTSSC3 groups most highly expressed TSSC3, which were not detected in tumors from siTSSC3 cells and were weakly detected in tumors from untransfected SaOS2 cells (Figure 3c) . Similarly, the frequency and intensity of Ki67 expression in tumor tissues derived from siTSSC3 cells were significantly higher than those from overTSSC3 and untransfected SaOS2 cells (Figure 3c and d) . Altogether, these results suggested a role of TSSC3 in tumor growth inhibition in vivo.
Induction of apoptosis by TSSC3 in vitro and in vivo TSSC3 was originally identified as a human apoptosis-related imprinted gene. To determine whether the observed reduction in growth of TSSC3 transfectants might be associated with an increase in basal apoptosis, we performed annexin V/PI analysis. Relative to the controls, early (lower right) and late apoptotic (upper right) cells were both prominently increased from 5.70 and 1.39% to14.70 and 9.97%, respectively, in cells overexpressing TSSC3 (Figure 4a ). In contrast, TSSC3 knockdown decreased the rate of early apoptosis by 4.04-fold and late apoptosis by 4.32-fold (Figure 4a) . Additionally, the percentage of cells in the sub-G/0 phase representative of apoptotic cells, assayed by PI staining, was also reduced along with TSSC3 downregulation (Figure 4b) . Results of the TUNEL assay also showed that the frequency and intensity of FITC-positive cells in overTSSC3 cells were significantly higher than those in controls (Figure 4c ). Additionally, cells overexpressing TSSC3 appeared rounded up and showed slower growth, decreased vitality and more detached apoptotic cells compared with controls by light microscopy. The overTSSC3 cells also showed apoptotic features by transmission electron microscopy. Nuclear membranes were irregular, and the crescent nuclei became condensed and fragmented, with vacuoles ( Figure 4d , blue arrows) in the cytoplasm and apoptotic bodies (Figure 4d, red arrow) .
To further investigate whether induction of TSSC3 caused apoptosis in vivo, immunofluorescence analysis and TUNEL assays were performed on tumors developed from overCON and overTSSC3 cells. Compared with the effect of overCON cells, the overTSSC3-derived tumors had obviously increased TSSC3 and TUNEL staining while TSSC3 expression and DNA fragmentation were co-localized, indicating that TSSC3 overexpression induced apoptosis in tumor tissues (Figure 4e) . The results of these independent assays demonstrated that constitutive expression of TSSC3 in SaOS2 cells was associated with an increase in basal apoptosis both in vitro and in vivo.
Activation of mitochondrial apoptosis pathway by TSSC3 in SaOS2 cells
Two signaling pathways are implicated in the apoptotic cascade, the cell surface death receptor and the mitochondria-initiated pathways. As shown in Figure 5a , qRT-PCR analysis indicated that upregulation of TSSC3 obviously increased the expression of caspase3, TSSC3 mediates apoptosis in osteosarcoma a downstream effector and common molecule of the apoptosis pathway, and Cyt c, an indicator of mitochondria pathway activation, as well as the Bax:Bcl-2 ratio, which plays an important role in determining the mitochondria apoptotic pathway. Conversely, downregulation of TSSC3 decreased expression of those molecules.
Apoptotic signal transduction via the intrinsic pathway is initiated by mitochondrial damage that triggers a disruption of the mitochondrial membrane potential (DW) resulting in membrane permeabilization and the release of apoptogenic factor such as Cyt c from the mitochondria (14, 15) . To further confirm that the increased expression levels of Cyt c concomitant with the translocation of Cyt c from mitochondria to cytosol, we therefore, used the lipophilic cationic agent JC-1, which is a marker of mitochondrial activity to evaluate the changes in overTSSC3 cells. Red fluorescence represented the mitochondrial aggregate form of JC-1 with high DW in normal cells. Green fluorescence represented the monomeric form of JC-1 with low DW in apoptotic cells. The ratio of green/red fluorescence intensities of JC-1 was scored as the apoptosis induced by the release of Cyt c. As shown in Figure 5d , overCON cells showed orange-red spots, indicating healthy mitochondria with an aggregated phenotype, whereas overTSSC3 cells showed diffuse green fluorescence approximate to the positive control because of decrease in DW, refiecting the transformation of JC-1 aggregates into monomers when mitochondrial membrane becomes depolarized. The overTSSC3 cells had a significantly increased ratio of green/red fluorescence intensities of JC-1 from 0.90 ± 0.04 to 4.31 ± 0.87.
As for death receptor signaling molecules, Fas was reduced, whereas Flip was increased in overTSSC3 cells compared with that All these results demonstrated that TSSC3 increased basal apoptosis mainly by activation of the mitochondrial apoptosis pathway.
Enhanced sensitivity of SaOS2 cells to chemotherapeutic agents by TSSC3 through increasing apoptosis
To examine whether expression of TSSC3 enhances sensitivity of osteosarcoma cells to chemotherapeutic agents, overTSSC3 cells and overCON cells were cultured in the presence of cisplatin and epirubicin for 24 h, followed by annexin V/PI and TUNEL staining. The intensity of annexin V staining was strongly increased in overTSSC3 cells (Figure 6a ), especially for late apoptotic cells (upper right). The TUNEL assay also showed that the intensity of FITC staining of overTSSC3 cells was significantly higher than that of overCON cells (Figure 6b ). Furthermore, we used immunofluorescence and western blot assays to detect the expression of apoptotic molecules after 24 h of cisplatin and epirubicin exposure. The overTSSC3 cells displayed a higher fluorescence intensity of cleaved caspase3 than the controls (Figure 6c ). Western blot analysis also showed an obvious increase in expression of Cyt c, cleaved caspase3 and cleaved PARP, a substrate of the caspase3 proenzyme, in overTSSC3 cells relative to those in overCON cells (Figure 6d ). Additionally, overTSSC3 cells after 24 h cisplatin exposure significantly increased JC-1 monomeric forms, which apparently improved the ratio of green/red fluorescence intensities of JC-1 compared with the control (from 1.33 ± 0.67 to 6.73 ± 1.65), suggesting enhanced disruption of the mitochondrial membrane potential and the release of Cyt c in TSSC3-induced apoptosis after chemotherapeutic agents exposure (Figure 6e ). In contrast, siTSSC3 cells became more resistant to chemotherapeutic agents as shown by annexin V/PI staining ( Figure 6a ) and western blot analysis (Supplementary Figure 2b is available at Carcinogenesis Online). These results indicated that constitutive TSSC3 expression clearly enhanced the sensitivity of osteosarcoma cells to chemotherapeutic agents by increasing apoptosis.
Discussion
Unlike other cancers, no consistent chromosomal alterations with diagnostic, therapeutic or prognostic importance have been found in osteosarcoma, and the karyotypes are also highly inconsistent between tumors. Nevertheless, events that may be important in the pathogenesis of osteosarcoma have been identified. The development and progression of osteosarcoma from normal human cells is a complex multistep process involving alterations in the expression and function of a variety of genes (16) . In recent years, genomic imprinting, an epigenetic modification of a genetic locus leading to monoallelic expression, has been reported to contribute to tumorigenesis by predisposing individuals to cancer (17) . Our laboratory previously found that the apoptosis-related imprinting gene TSSC3 was differentially expressed during malignant transformation of the human osteoblast line hFOB1.19. The maternally expressed TSSC3 gene, imprinted in placenta and most fetal tissues (18) , has been implicated in early growth and development (19) (20) (21) . Increased TSSC3 expression is also associated with placenta growth restriction (22, 23) and low birth weight (24) . Previous studies showed that downregulation of the PHLDA1 gene (also known as TDAG51), a homolog of TSSC3, is associated with progression of several cancers, including breast cancer (25, 26) and melanoma (27) . However, only a few studies have reported on the relationship between TSSC3 and human cancers, including the loss of TSSC3 expression in complete hydatidiform moles (28), Wilms' tumors (29) and brain cancer (30) . Moreover, these TSSC3 mediates apoptosis in osteosarcoma studies generally focused on the expression level and the imprinting status of TSSC3 in those cancers, and no reports on the TSSC3 expression pattern, its functional role and involved mechanisms in pathogenesis of osteosarcoma have been published. In this study, we first found that TSSC3 expression was downregulated in osteosarcoma cell lines and tissues compared with osteoblasts and matched normal tissues. Therefore, we hypothesized that TSSC3 may play a potential tumor suppressor role with negative growth regulation by inducing cell apoptosis in osteosarcoma.
The fact that TSSC3 is expressed from the maternal allele is consistent with a potential growth inhibitory effect, which can suppress fetal development and placenta growth during embryogenesis (16) . The homolog gene PHLDA1/TDGA51 of TSSC3 has been demonstrated to promote apoptosis in a T lymphocyte cell line (31) and neuronal cells (32) and also to participate in cancer development and progression through suppressing cell growth and enhancing programmed cell death (25) (26) (27) . Unpublished results from our laboratory have also shown that 5-aza-CdR dose dependently induced cell growth arrest and apoptosis by upregulating TSSC3 in osteosarcoma cell lines. Certainly, only relying on the expression pattern of a gene in cancer cells and tissue is insufficient to reach a conclusion on its exact functional role and the inhibition of DNA methylation by 5-aza-CdR lacks site specificity. In order to confirm the function of TSSC3, we directly manipulated the expression of TSSC3 by establishing SaOS2 overexpressing or knockdown stable cell lines. The selection of SaOS2 cells for these studies was based on three major pieces of evidence: (i) SaOS2 cell lines, used in a broad spectrum of biomedical research, show low but not lack of endogenous TSSC3 expression, and therefore could be regulated bidirectionally (33); (ii) SaOS2 cells markedly upregulated the TSSC3 after 5-aza-CdR treatment compared with other osteosarcoma cell lines, suggesting that it could be a model of imprinted gene research and (iii) SaOS2 cells are deficient in expression of TP53 and RB, two crucial genes involved in apoptosis, and are less sensitive to chemotherapeutic drugs than other osteosarcoma cell lines (33) . These genetic contexts of SaOS2 support its use for studies of apoptosis-related genes and chemotherapy effects in osteosarcoma.
In the present study, constitutive TSSC3 expression in SaOS2 cells was associated with reduced cell proliferation examined by CCK8, plate colony formation assay and Ki67 staining as well as cell cycle arrest in G 0 /G 1 in vitro. Most encouragingly, overexpression of TSSC3 in SaOS2 cells resulted in reduced mean tumor volumes by 87% at 7 weeks after injection into mice. The observed tumor growth inhibition may reflect an increased sensitivity to apoptosis. In fact, under normal growth conditions, overTSSC3 cells displayed broad evidence of an increased basal apoptosis rate in vitro as assessed by annexin V/PI and TUNEL staining. Injected overTSSC3 cells also resulted in simultaneously increased TSSC3 expression and FITCdeoxyuridine triphosphate incorporation in xenograft tumor tissue. Without exception, the reverse patterns were observed in TSSC3 knockdown cells. Collectively, these in vitro and in vivo findings provide a persuasive conclusion: functionally activated TSSC3 indeed plays a tumor suppressor role with negative growth regulation through inducing cell apoptosis in osteosarcoma.
Evading apoptosis is a hallmark of cancer cells, enabling them to survive despite death-inducing signals (4). The apoptotic molecular mechanisms in cancer lie in the alterations of related signaling pathways. The known tumor suppressor gene P53 and RB gene are the most frequently mutated in osteosarcoma (1) . Mutations in the P53 gene can lead to resistance to apoptosis by removing a key component of the DNA damage sensor that induces the apoptotic effector cascade; meanwhile, the RB gene, to which nearly all antiproliferative signals converge, can block proliferation by altering transcription factors that govern the progression of the cell from G 1 to S phase. TSSC3 in SaOS2 cells may mimic and replace the functions of the P53 and RB genes. The SaOS2 cell line used in this study is deficient in the P53 signaling pathway, which plays a crucial role during escape from apoptosis and acquisition of drug-resistance in osteosarcoma cells. Therefore, this characteristic can explain the high resistance to apoptosis and well-known insensitivity to chemotherapeutic drugs and radiotherapy in SaOS2 cells. In fact, neither cleaved capase3 nor cleaved PARP were detected in SaOS2 cells in normal growth conditions or even after exposure to chemotherapeutic reagents (cisplatin or epirubicin), consistent with their known low apoptotic rate. However, constitutive expression of TSSC3 in osteosarcoma cells resulted in notably enhanced sensitivity to apoptosis induced by cisplatin and epirubicin. As discussed above, these results indicated TSSC3 not only increased the early apoptotic rate but also late apoptotic rate and necrosis. It has been reported that the level of necrosis induced by chemotherapy in primary osteosarcoma serves as an extremely important prognostic indicator for long-term survival (34) . Complementation with the PHLDA1/TDAG51 gene was shown to restore Fas expression and susceptibility to apoptosis in a mutant T lymphocyte cell line, which was selected for resistance to apoptosis (31) . However, PHLDA1 is not associated with Fas expression in neuronal cells (32) or in human T cells (35) , and it is required for upregulation of cleaved caspase9 in melanoma (27) . Moreover, TDAG51 is also not essential for Fas-mediated apoptosis in TDAG51-deficient mice (36).
Lee et al. (7) found coexpression of TSSC3 and Fas in multiple human tissues through northern blotting, implicating TSSC3 in Fasmediated apoptosis. However, TSSC3 expression was associated with increases in components of the mitochondrial pathway in our study, not only in normal conditions but also after drug treatment, doubtlessly suggesting that TSSC3 could enhance the mitochondrial-mediated apoptotic pathway in osteosarcoma. Interestingly, we found TSSC3 was required for downregulation of Fas and upregulation of Flip. Recent studies found that Fas/FasL interactions may have tumor-promoting functions, depending on the cell type and other conditions through activation of c-jun N-terminal kinase, nuclear factor-kappaB or PI3K/ AKT signaling pathways (37) . The extrinsic Fas/FasL signaling pathway may act in an antiapoptotic capacity and promote cancer in SaOS2 cells. Therefore, TSSC3 could induce apoptosis by upregulation of the intrinsic mitochondria pathway and downregulation of the extrinsic death receptor pathway in SaOS2 cells. Previous studies have also reported that insulin-like growth factors-I could induce TDAG51 expression via the p38 MAPK pathway and play an important role in the antiapoptotic effects of insulin-like growth factors-I in NIH-3T3 cells (38) . The proand antiapoptotic effects of the PQR protein (proline-glutamine-rich protein) related to TSSC3 appears to be dependent on the cell type and environment. Therefore, the observations above may be due to different cell types, genetic context and study systems, especially with TSSC3 being an imprinted gene. Taken together, our results demonstrated that TSSC3 plays a functional role in osteosarcoma through a mitochondrialmediated apoptosis pathway in a P53-independent manner.
The TSSC3 complementary DNA, composed of 770 bp containing a 223 bp intron with a 152 amino acid open reading frame, resembles retroelements by being small and containing few and small introns (19) . As mentioned above, two proteins highly similar to TSSC3 have been identified: murine TDAG51 which is localized in the nucleus and acts as a transcription factor regulating Fas expression (31) , and the PQR protein implicated in the protein-protein interactions and transcription activation in some homeobox proteins (32) , suggesting that TSSC3 may also function as a transcriptional activator. PQR can be induced by a variety of signaling cascades such as T cell receptor stimulation (31), endoplasmic reticulum stress (39) , as well as growth factors (35, 38) . Although TSSC3 was observed in the cytoplasm of osteosarcoma under normal culture conditions, it contains the specific domains noted above and a pleckstrin homology region, which may mediate interaction with cellular membranes (18) . These sequence elements suggest that it can be translocated into the nucleus under certain conditions (external stimuli) and function to inhibit protein synthesis (40) . Additionally, the Pleckstrin homology-related family of proteins has been reported to be involved in cross talk with multiple critical pathways regulating tumorigenesis. PHLDA3 is a P53 target gene that contributes to P53-dependent apoptosis by inhibiting Akt activity in lung endocrine tumors (41) , and TDAG51 serves as a negative regulator of extracellular signalregulated kinase signaling and opposes extracellular signal-regulated kinase-mediated transformation in breast epithelial cells (42) . Therefore, we speculate that TSSC3 may contribute to development and progression of osteosarcoma by interaction with other tumorigenesis pathways.
Furthermore, level of a protein encoded by an imprinted gene depends upon expression of a single allele. Abnormality in only one of the parental alleles can result in malignant transformation such as Wilms' tumors (43) , chronic myeloid leukemia (44) and hepatocellular (45) and lung cancer (46) . Therefore, individuals with misregulation of the imprinting control region, including loss of imprinting of oncogene or LOH (loss of heterozygosity) of an anti-oncogene, are significantly more susceptible to tumors than those with wild-type sequences. Loss of imprinting has also been observed in osteosarcoma (47) . The mechanisms of imprinting control region misregulation mainly involve either differentially methylated regions (48, 49) or untranslated RNAs (50, 51) . The human chromosome 11p15.5 imprinted domain to which TSSC3 maps is especially relevant to the relationship between imprinting status and tumorigenesis. Recently, IGF2 (52), H19 (53) and p57 KIP2 (54) of this region were also found to be involved in the disregulated cell growth and differentiation characteristics of these tumors. IGF2, unlike TSSC3, is expressed from the paternal allele and thought to have an antiapoptotic and growth promotion effect, as highlighted in our previous study (55) . Its expression pattern may also be related to TSSC3 expression in osteosarcoma tissues (data not shown). Last but not the least, our laboratory found that the TSSC3 gene showed comparable strong expression in osteoblasts but progressively reduced expression in osteosarcoma cell lines and their derived anoikis-resistance cell lines (data not shown), also suggesting its importance in the development and progression of osteosarcoma. However, further studies are needed to better determine: (i) the imprinting status of TSSC3 and the exact mechanisms underlying its regulation during development and progression of osteosarcomas; (ii) the proteins interacting with TSSC3; (iii) the cross talk with other critical tumorigenesis-related regulatory pathways, e.g. transmission of extracellular signals into the nucleus by TSSC3 translocation, thereby influencing cell apoptosis and survival and (iv) the function of TSSC3 and the mechanisms involved in anoikis resistance of osteosarcoma.
In summary, our study provides the first evidence to support that TSSC3 plays a tumor suppressor role in human osteosarcoma through growth inhibition and induction of the mitochondrial apoptosis pathway in vitro and in vivo. These findings may offer important clues to understanding how TSSC3 participates in osteosarcoma development. Additional studies to clarify the underlying mechanism will be beneficial for developing TSSC3-based therapeutic strategies to treat osteosarcoma.
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